Is This a 737 Max Moment for Brolucizumab?
Publication
, Journal Article
Rosenfeld, PJ; Browning, DJ
Published in: Am J Ophthalmol
August 2020
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am J Ophthalmol
DOI
EISSN
1879-1891
Publication Date
August 2020
Volume
216
Start / End Page
A7 / A8
Location
United States
Related Subject Headings
- Wet Macular Degeneration
- Vascular Endothelial Growth Factor A
- Uveitis
- Retinal Vasculitis
- Ophthalmology & Optometry
- Intravitreal Injections
- Humans
- Drug-Related Side Effects and Adverse Reactions
- Antibodies, Monoclonal, Humanized
- Angiogenesis Inhibitors
Citation
APA
Chicago
ICMJE
MLA
NLM
Rosenfeld, P. J., & Browning, D. J. (2020). Is This a 737 Max Moment for Brolucizumab? Am J Ophthalmol, 216, A7–A8. https://doi.org/10.1016/j.ajo.2020.05.012
Rosenfeld, Philip J., and David J. Browning. “Is This a 737 Max Moment for Brolucizumab?” Am J Ophthalmol 216 (August 2020): A7–8. https://doi.org/10.1016/j.ajo.2020.05.012.
Rosenfeld PJ, Browning DJ. Is This a 737 Max Moment for Brolucizumab? Am J Ophthalmol. 2020 Aug;216:A7–8.
Rosenfeld, Philip J., and David J. Browning. “Is This a 737 Max Moment for Brolucizumab?” Am J Ophthalmol, vol. 216, Aug. 2020, pp. A7–8. Pubmed, doi:10.1016/j.ajo.2020.05.012.
Rosenfeld PJ, Browning DJ. Is This a 737 Max Moment for Brolucizumab? Am J Ophthalmol. 2020 Aug;216:A7–A8.
Published In
Am J Ophthalmol
DOI
EISSN
1879-1891
Publication Date
August 2020
Volume
216
Start / End Page
A7 / A8
Location
United States
Related Subject Headings
- Wet Macular Degeneration
- Vascular Endothelial Growth Factor A
- Uveitis
- Retinal Vasculitis
- Ophthalmology & Optometry
- Intravitreal Injections
- Humans
- Drug-Related Side Effects and Adverse Reactions
- Antibodies, Monoclonal, Humanized
- Angiogenesis Inhibitors